CSL Intrinsic Valuation and Fundamental Analysis - CSL Ltd - Alpha Spread

CSL Ltd
ASX:CSL

Watchlist Manager
CSL Ltd Logo
CSL Ltd
ASX:CSL
Watchlist
Price: 295.78 AUD 0.56% Market Closed
Market Cap: 143.2B AUD
Have any thoughts about
CSL Ltd?
Write Note

Intrinsic Value

The intrinsic value of one CSL stock under the Base Case scenario is 234.43 AUD. Compared to the current market price of 295.78 AUD, CSL Ltd is Overvalued by 21%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

CSL Intrinsic Value
234.43 AUD
Overvaluation 21%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
CSL Ltd

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for CSL cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about CSL?
Bearish
Neutral
Bullish

Fundamental Analysis

Summary

 

 

 

 

View All Risks & Rewards
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

AI Assistant
AI Assistant
Ask me anything about CSL Ltd

Provide an overview of the primary business activities
of CSL Ltd.

What unique competitive advantages
does CSL Ltd hold over its rivals?

What risks and challenges
does CSL Ltd face in the near future?

Summarize the latest earnings call
of CSL Ltd.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for CSL Ltd.

Provide P/S
for CSL Ltd.

Provide P/E
for CSL Ltd.

Provide P/OCF
for CSL Ltd.

Provide P/FCFE
for CSL Ltd.

Provide P/B
for CSL Ltd.

Provide EV/S
for CSL Ltd.

Provide EV/GP
for CSL Ltd.

Provide EV/EBITDA
for CSL Ltd.

Provide EV/EBIT
for CSL Ltd.

Provide EV/OCF
for CSL Ltd.

Provide EV/FCFF
for CSL Ltd.

Provide EV/IC
for CSL Ltd.

Show me price targets
for CSL Ltd made by professional analysts.

What are the Revenue projections
for CSL Ltd?

How accurate were the past Revenue estimates
for CSL Ltd?

What are the Net Income projections
for CSL Ltd?

How accurate were the past Net Income estimates
for CSL Ltd?

What are the EPS projections
for CSL Ltd?

How accurate were the past EPS estimates
for CSL Ltd?

What are the EBIT projections
for CSL Ltd?

How accurate were the past EBIT estimates
for CSL Ltd?

Compare the revenue forecasts
for CSL Ltd with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of CSL Ltd and its key competitors using the latest financial data.

Compare historical revenue growth rates
of CSL Ltd against its competitors.

Analyze the profit margins
(gross, operating, and net) of CSL Ltd compared to its peers.

Compare the P/E ratios
of CSL Ltd against its peers.

Discuss the investment returns and shareholder value creation
comparing CSL Ltd with its peers.

Analyze the financial leverage
of CSL Ltd compared to its main competitors.

Show all profitability ratios
for CSL Ltd.

Provide ROE
for CSL Ltd.

Provide ROA
for CSL Ltd.

Provide ROIC
for CSL Ltd.

Provide ROCE
for CSL Ltd.

Provide Gross Margin
for CSL Ltd.

Provide Operating Margin
for CSL Ltd.

Provide Net Margin
for CSL Ltd.

Provide FCF Margin
for CSL Ltd.

Show all solvency ratios
for CSL Ltd.

Provide D/E Ratio
for CSL Ltd.

Provide D/A Ratio
for CSL Ltd.

Provide Interest Coverage Ratio
for CSL Ltd.

Provide Altman Z-Score Ratio
for CSL Ltd.

Provide Quick Ratio
for CSL Ltd.

Provide Current Ratio
for CSL Ltd.

Provide Cash Ratio
for CSL Ltd.

What is the historical Revenue growth
over the last 5 years for CSL Ltd?

What is the historical Net Income growth
over the last 5 years for CSL Ltd?

What is the current Free Cash Flow
of CSL Ltd?

Discuss the annual earnings per share (EPS)
trend over the past five years for CSL Ltd.

Business Breakdown

CSL Ltd. is a global biotechnology powerhouse, rooted in Australia, that specializes in developing and delivering innovative therapies for people with serious and rare medical conditions. Founded in 1916, CSL originally focused on producing blood serum for treating was patients during World War I. Over the years, the company has evolved remarkably, moving into the biopharmaceutical realm with a strong focus on immunology, hematology, and respiratory diseases. Today, CSL is best known for its leading product, antibody therapies derived from human plasma, providing vital treatments for conditions such as hemophilia, primary immunodeficiency, and Guillain-Barré Syndrome. Investors appreciate CS...

Read More
Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
CSL Ltd

Current Assets 10.8B
Cash & Short-Term Investments 1.7B
Receivables 3B
Other Current Assets 6.1B
Non-Current Assets 27.3B
Long-Term Investments 163m
PP&E 9.7B
Intangibles 16.3B
Other Non-Current Assets 1.1B
Current Liabilities 5B
Accounts Payable 3.3B
Short-Term Debt 14m
Other Current Liabilities 1.6B
Non-Current Liabilities 15.7B
Long-Term Debt 11.2B
Other Non-Current Liabilities 4.5B
Efficiency

Earnings Waterfall
CSL Ltd

Revenue
14.8B USD
Cost of Revenue
-7.1B USD
Gross Profit
7.7B USD
Operating Expenses
-3.9B USD
Operating Income
3.8B USD
Other Expenses
-1.2B USD
Net Income
2.6B USD

Free Cash Flow Analysis
CSL Ltd

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

CSL Profitability Score
Profitability Due Diligence

CSL Ltd's profitability score is 59/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Positive Operating Income
Positive Free Cash Flow
Positive 3-Year Average ROE
59/100
Profitability
Score

CSL Ltd's profitability score is 59/100. The higher the profitability score, the more profitable the company is.

CSL Solvency Score
Solvency Due Diligence

CSL Ltd's solvency score is 60/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Low D/E
Long-Term Solvency
60/100
Solvency
Score

CSL Ltd's solvency score is 60/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

CSL Price Targets Summary
CSL Ltd

Wall Street analysts forecast CSL stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for CSL is 322.83 AUD with a low forecast of 233.7 AUD and a high forecast of 369.6 AUD.

Lowest
Price Target
233.7 AUD
21% Downside
Average
Price Target
322.83 AUD
9% Upside
Highest
Price Target
369.6 AUD
25% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for CSL?

Click here to dive deeper.

Dividends

Dividend Yield
Lowest
Average
Highest
Dividend Per Share
N/A
Growth 3Y
Growth 5Y
Growth 10Y
Dividend Safety Score
Very
Unsafe
Unsafe
Safe
Very
Safe
0
25
50
75
100
Previous Payment
-
Today
Next Payment
-
Today
Oct 13, 2024
Previous Payment
-
Next Payment
-
Ex-Dividend Date
-
Want to learn more about CSL dividends?

Click here to dive deeper.

Shareholder Yield

Current shareholder yield for CSL is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
Lowest
Average
Highest
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Profile

CSL Ltd Logo
CSL Ltd

Country

Australia

Industry

Biotechnology

Market Cap

142.9B AUD

Dividend Yield

1.35%

Description

CSL Ltd. is a biopharmaceutical company, which engages in the manufacture, marketing, and distribution of biopharmaceutical and allied products. The company is headquartered in Melbourne, Victoria and currently employs 25,000 full-time employees. The firm is engaged in developing and delivering biotherapies and influenza vaccines that treat people with serious diseases and chronic medical conditions. The company offers treatments for people who are living with conditions in immunology, hematology, cardiovascular and metabolic, respiratory, and transplant therapeutic areas. The firm operates through two segments: CSL Behring and Seqirus. CSL Behring manufactures, markets, and develops plasma therapies (plasma products and recombinants), conducts early-stage research on plasma and non-plasma therapies, excluding influenza, receives license and royalty income from the commercialization of intellectual property and undertakes the administrative and corporate function required to support the Company. Seqirus segment manufactures and distributes non-plasma biotherapeutic products and develops influenza related products. Its products include PRIVIGEN, IDELVION and AFSTYLA.

Contact

VICTORIA
Melbourne
45 Poplar Road,, Parkville
+61393891911.0
www.csl.com

IPO

1994-06-08

Employees

25 000

Officers

See Also

Discover More
What is the Intrinsic Value of one CSL stock?

The intrinsic value of one CSL stock under the Base Case scenario is 234.43 AUD.

Is CSL stock undervalued or overvalued?

Compared to the current market price of 295.78 AUD, CSL Ltd is Overvalued by 21%.

Back to Top